BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260516T010212
CREATED:20211130T161037Z
LAST-MODIFIED:20211130T161037Z
UID:32293-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Blood Disorders
DESCRIPTION:In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies\, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field\, enabling you to progress your pipeline to address the significant unmet need in this field. \nFocused specifically on hemophilia\, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches\, this event is an invaluable opportunity to learn the realities of durability challenges\, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field. \nIncorporating insights from translational\, clinical and commercial industry experts\, as well as leading clinicians actively involved in late-stage trials\, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies\, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption. \nTo know more visit: https://ter.li/u41qa2
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-blood-disorders/
LOCATION:Boston Logan Airport Hotel\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220402
DTSTAMP:20260516T010212
CREATED:20211210T094616Z
LAST-MODIFIED:20211210T094922Z
UID:32479-1648512000-1648857599@www.pharmajournalist.com
SUMMARY:12th World ADC London
DESCRIPTION:12th Annual World ADC London\n29th March – 1st April 2022\nLondon \nThe ADC field is going from strength to strength\, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively\, bringing the total number of commercially available ADCs to 11. \nReturning in-person in from 29th March – 1st April\, be part of the 12th Annual World ADC London and reconnect with 400+ of your peers at the forefront of ADC drug development. \nAfter in-depth research with key opinion leaders within the ADC field\, this is your most extensive programme to-date addressing the most pressing challenges facing ADC developers from discovery through to late phase manufacturing. \nTake a look at the brand-new agenda here! \nThe four-streamed\, four-day unrivalled programme with 75+ industry-leading speakers will equip you with the insights and connections to nourish your current pipelines of ADCs\, discover the next generation of non-traditional ADCs\, and confidently define your manufacturing processes. \nRegister now and join the likes of the likes of Daiichi Sankyo\, AstraZeneca\, ADC Therapeutics\, Seagen and many more to work collaboratively to overcome the distinct challenges ADC drug development holds and maximise the therapeutic window of ADCs.
URL:https://www.pharmajournalist.com/event/12th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260516T010212
CREATED:20220107T124627Z
LAST-MODIFIED:20220107T124627Z
UID:32748-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:Next Generation Kinase Inhibitors Summit
DESCRIPTION:Celebrating 20 years of FDA approval and high efficacy profiles\, kinase inhibitors have changed the face of oncology treatment. However\, increasing resistance and safety issues limit the success of existing kinase inhibitor classes. \nThe inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond. \nBoasting 20+ speakers\, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery\, R&D and clinical development\, this event is a unique opportunity for your team to identify and target the undruggable\, elevate drug design for improved target selectivity\, overcome the blood brain barrier and rationalize combinations for more durable responses. \nCollaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity\, maximal durability to deliver the best clinical outcomes. \nTo know more visit: https://kinase-inhibitors-summit.com/
URL:https://www.pharmajournalist.com/event/next-generation-kinase-inhibitors-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR